Sanofi, in partnership with Regeneron, experienced a setback with mixed results in key trials for the respiratory drug meant for Chronic Obstructive Pulmonary Disease (COPD). The outcome has caused reactions among investors, leading to a fall in Sanofi shares. Nevertheless, the company continues its active role in other fields, including raising Type 1 diabetes awareness and exploring vaccine production in Vietnam with local partners. Another highlight is a $470 million deal to acquire Vigil Neuroscience, a move aimed at boosting the neurological pipeline. The company has also vowed to invest a minimum of $20 billion in the U.S by 2030. However, the company’s decision to terminate its partnership with IGM leading to an 80% staff cut sparked concerns. Additionally, Sanofi’s meningococcal vaccine received US FDA approval for utilization in infants, a noteworthy achievement in public health.
Sanofi News Analytics from Mon, 23 Sep 2024 12:06:18 GMT to Sat, 31 May 2025 17:19:33 GMT -
Rating -2
- Innovation 6
- Information 7
- Rumor -4
